Joenja — Medical Mutual
Activated Phosphoinositide 3-kinase Delta Syndrome (APDS), initial therapy
Initial criteria
- Patient is ≥ 12 years of age
- Patient weighs ≥ 45 kg
- Patient has a genetic phosphoinositide 3-kinase delta (PI3Kδ) mutation with a variant in PIK3CD and/or PIK3R1 genes
- Patient has at least one clinical finding or manifestation consistent with APDS
- The medication is prescribed by or in consultation with an immunologist or a physician who treats patients with primary immune deficiencies
Approval duration
6 months